FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Acceptance based on results from the Phase 3 KEYNOTE-A18 trial, which showed a statistically significant and clinically meaningful improvement in progression-free survival in these patients

...

Related Keywords

Canada ,United States ,Gursel Aktan ,Twitter ,Youtube ,Drug Administration ,Statement Of Merck Co Inc ,Facebook ,Merck Research Laboratories ,Instagram ,Merck Co Inc ,Foundation Inc ,Exchange Commission ,European Network For Gynaecological Oncology Trial ,Linkedin ,Biologics License Application ,Prescription Drug User Fee Act ,Merck Research ,Combined Positive Score ,European Network ,Gynaecological Oncology Trial ,Among Merck ,Selected Important Safety ,Important Safety Information ,Fatal Immune Mediated Adverse ,Which Can Present With Diabetic ,Nervous System ,Connective Tissue ,Patients With Multiple ,Neck Squamous Cell ,Bacillus Calmette Guerin Unresponsive ,Mismatch Repair Deficient ,Mismatch Repair Deficient Colorectal ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,Markets ,